- Home
- AUTL vs PAYS Comparison
AUTL vs PAYS Comparison
Compare AUTL & PAYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AUTL | PAYS |
|---|---|---|
| Founded | 2014 | 2001 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 532.3M | 485.8M |
| IPO Year | 2025 | 2020 |
Fundamental Metrics
Financial Performance| Metric | AUTL | PAYS |
|---|---|---|
| Price | $2.15 | $13.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $8.50 | ★ $9.42 |
| AVG Volume (30 Days) | ★ 2.4M | 702.5K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 85.71 |
| EPS | N/A | ★ 0.20 |
| Revenue | $10,120,000.00 | ★ $24,120,434.00 |
| Revenue This Year | $80.32 | $33.83 |
| Revenue Next Year | $53.96 | $14.89 |
| P/E Ratio | ★ N/A | $65.10 |
| Revenue Growth | ★ 496.00 | N/A |
| 52 Week Low | $1.18 | $3.08 |
| 52 Week High | $2.43 | $13.15 |
Technical Indicators
Market Signals| Indicator | AUTL | PAYS |
|---|---|---|
| Relative Strength Index (RSI) | 62.72 | 85.58 |
| Support Level | $1.31 | $4.94 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.19 | 0.59 |
| MACD | 0.05 | 0.32 |
| Stochastic Oscillator | 70.10 | 98.29 |
Price Performance
Historical ComparisonAbout AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.
About PAYS Paysign Inc.
PaySign Inc is a provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing designed for businesses, consumers, and government institutions. The company creates customized payment solutions for clients across industries, including pharmaceutical, healthcare, hospitality, and retail. The The company generates revenues from pharma card programs through card program management fees, transaction claim processing fees, interchange fees, customer service fees, other billable service fees and settlement income and other revenues are generated through cardholder fees, interchange fees, program management fees, load fees and breakage.